These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 25228699)

  • 1. Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.
    Liu Z; Galemmo RA; Fraser KB; Moehle MS; Sen S; Volpicelli-Daley LA; DeLucas LJ; Ross LJ; Valiyaveettil J; Moukha-Chafiq O; Pathak AK; Ananthan S; Kezar H; White EL; Gupta V; Maddry JA; Suto MJ; West AB
    J Biol Chem; 2014 Nov; 289(47):32937-51. PubMed ID: 25228699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold.
    Galatsis P; Henderson JL; Kormos BL; Han S; Kurumbail RG; Wager TT; Verhoest PR; Noell GS; Chen Y; Needle E; Berger Z; Steyn SJ; Houle C; Hirst WD
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4132-40. PubMed ID: 25113930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dual enzyme LRRK2 hydrolyzes GTP in both its GTPase and kinase domains in vitro.
    Liu Z; West AB
    Biochim Biophys Acta Proteins Proteom; 2017 Mar; 1865(3):274-280. PubMed ID: 27939437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities.
    Webber PJ; Smith AD; Sen S; Renfrow MB; Mobley JA; West AB
    J Mol Biol; 2011 Sep; 412(1):94-110. PubMed ID: 21806997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The G2019S pathogenic mutation disrupts sensitivity of leucine-rich repeat kinase 2 to manganese kinase inhibition.
    Covy JP; Giasson BI
    J Neurochem; 2010 Oct; 115(1):36-46. PubMed ID: 20626563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A direct interaction between leucine-rich repeat kinase 2 and specific β-tubulin isoforms regulates tubulin acetylation.
    Law BM; Spain VA; Leinster VH; Chia R; Beilina A; Cho HJ; Taymans JM; Urban MK; Sancho RM; Blanca Ramírez M; Biskup S; Baekelandt V; Cai H; Cookson MR; Berwick DC; Harvey K
    J Biol Chem; 2014 Jan; 289(2):895-908. PubMed ID: 24275654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATP-competitive LRRK2 inhibitors interfere with monoclonal antibody binding to the kinase domain of LRRK2 under native conditions. A method to directly monitor the active conformation of LRRK2?
    Gillardon F; Kremmer E; Froehlich T; Ueffing M; Hengerer B; Gloeckner CJ
    J Neurosci Methods; 2013 Mar; 214(1):62-8. PubMed ID: 23318290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a mechanism-based high-throughput screen assay for leucine-rich repeat kinase 2--discovery of LRRK2 inhibitors.
    Liu M; Poulose S; Schuman E; Zaitsev AD; Dobson B; Auerbach K; Seyb K; Cuny GD; Glicksman MA; Stein RL; Yue Z
    Anal Biochem; 2010 Sep; 404(2):186-92. PubMed ID: 20566370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a high-throughput AlphaScreen assay measuring full-length LRRK2(G2019S) kinase activity using moesin protein substrate.
    Pedro L; Padrós J; Beaudet L; Schubert HD; Gillardon F; Dahan S
    Anal Biochem; 2010 Sep; 404(1):45-51. PubMed ID: 20434426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2.
    Li X; Moore DJ; Xiong Y; Dawson TM; Dawson VL
    J Biol Chem; 2010 Sep; 285(38):29569-76. PubMed ID: 20595391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities.
    Liu M; Dobson B; Glicksman MA; Yue Z; Stein RL
    Biochemistry; 2010 Mar; 49(9):2008-17. PubMed ID: 20146535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of the autophosphorylation sites of LRRK2.
    Kamikawaji S; Ito G; Iwatsubo T
    Biochemistry; 2009 Nov; 48(46):10963-75. PubMed ID: 19824698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LRRK2 Facilitates tau Phosphorylation through Strong Interaction with tau and cdk5.
    Shanley MR; Hawley D; Leung S; Zaidi NF; Dave R; Schlosser KA; Bandopadhyay R; Gerber SA; Liu M
    Biochemistry; 2015 Aug; 54(33):5198-208. PubMed ID: 26268594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease.
    Domingos S; Duarte T; Saraiva L; Guedes RC; Moreira R
    Future Med Chem; 2019 Aug; 11(15):1953-1977. PubMed ID: 31517532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LRRK2 autophosphorylation enhances its GTPase activity.
    Liu Z; Mobley JA; DeLucas LJ; Kahn RA; West AB
    FASEB J; 2016 Jan; 30(1):336-47. PubMed ID: 26396237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations.
    Sheng Z; Zhang S; Bustos D; Kleinheinz T; Le Pichon CE; Dominguez SL; Solanoy HO; Drummond J; Zhang X; Ding X; Cai F; Song Q; Li X; Yue Z; van der Brug MP; Burdick DJ; Gunzner-Toste J; Chen H; Liu X; Estrada AA; Sweeney ZK; Scearce-Levie K; Moffat JG; Kirkpatrick DS; Zhu H
    Sci Transl Med; 2012 Dec; 4(164):164ra161. PubMed ID: 23241745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity.
    Reichling LJ; Riddle SM
    Biochem Biophys Res Commun; 2009 Jun; 384(2):255-8. PubMed ID: 19397894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triazolopyridazine LRRK2 kinase inhibitors.
    Franzini M; Ye XM; Adler M; Aubele DL; Garofalo AW; Gauby S; Goldbach E; Probst GD; Quinn KP; Santiago P; Sham HL; Tam D; Truong A; Ren Z
    Bioorg Med Chem Lett; 2013 Apr; 23(7):1967-73. PubMed ID: 23454015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2).
    Chan D; Citro A; Cordy JM; Shen GC; Wolozin B
    J Biol Chem; 2011 May; 286(18):16140-9. PubMed ID: 21454543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization.
    Nichols RJ; Dzamko N; Morrice NA; Campbell DG; Deak M; Ordureau A; Macartney T; Tong Y; Shen J; Prescott AR; Alessi DR
    Biochem J; 2010 Sep; 430(3):393-404. PubMed ID: 20642453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.